Evaluation and Management of Osteoarthritis (2).ppt

biruktesfaye27 66 views 37 slides May 02, 2023
Slide 1
Slide 1 of 37
Slide 1
1
Slide 2
2
Slide 3
3
Slide 4
4
Slide 5
5
Slide 6
6
Slide 7
7
Slide 8
8
Slide 9
9
Slide 10
10
Slide 11
11
Slide 12
12
Slide 13
13
Slide 14
14
Slide 15
15
Slide 16
16
Slide 17
17
Slide 18
18
Slide 19
19
Slide 20
20
Slide 21
21
Slide 22
22
Slide 23
23
Slide 24
24
Slide 25
25
Slide 26
26
Slide 27
27
Slide 28
28
Slide 29
29
Slide 30
30
Slide 31
31
Slide 32
32
Slide 33
33
Slide 34
34
Slide 35
35
Slide 36
36
Slide 37
37

About This Presentation

kkkkk


Slide Content

High Impact Rheumatology
Evaluation and Management
of Osteoarthritis

Osteoarthritis: Case 1
•A 65-year-old man comes to your office
complaining of knee pain that began insidiously
about a year ago. He has no other rheumatic
symptoms
•What further questions should you ask?
•What are the pertinent physical findings?
•Which diagnostic studies are appropriate?

OA: Symptoms and Signs
Pain is related to use
Pain gets worse
during the day
Minimal morning
stiffness (<20 min)
and after inactivity
(gelling)
Range of motion
decreases
Joint instability
Bony enlargement
Restricted movement
Crepitus
Variable swelling
and/or instability

OA Case 1: Radiographic Features
Joint space narrowing
Marginal osteophytes
Subchondral cysts
Bony sclerosis
Malalignment
NAILS THE
DIAGNOSIS

OA: Laboratory Tests
No specific tests
No associated laboratory abnormalities;
eg, sedimentation rate
Investigational: Cartilage degradation products in
serum and joint fluid

OA: Risk Factors
Why did this patient develop osteoarthritis?

OA: Risk Factors (cont’d)
Age: 75% of persons over age 70 have OA
Female sex
Obesity
Hereditary
Trauma
Neuromuscular dysfunction
Metabolic disorders

Case 1: Cause of Knee OA
On further questioning, patient recalls fairly
serious knee injury during sport event many
years ago
Therefore, posttraumatic OA is most likely
diagnosis

QuickTime™ and a
Photo CD Decompressor
are needed to use this picture Case 1: Prognosis
Natural history of OA: Progressive cartilage loss,
subchondral thickening, marginal osteophytes

OA: Case 2
A 75-year-old woman presents to your office with
complaints of pain and stiffness in both knees,
hips, and thumbs. She also has occasional back
pain
Family history reveals that her mother had similar
problems
On exam she has bony enlargement of both
knees, restricted ROM of both hips, squaring at
base of both thumbs, and multiple Heberden’s
and Bouchard’s nodes

Distribution of Primary OA
Primary OA typically
involves variable
number of joints in
characteristic locations,
as shown
Exceptions may occur,
but should trigger
consideration of
secondary causes of OA

0
20
40
60
80
20 40 60 80 Men
Age (years)
Prevalence of OA (%)0
20
40
60
80
20 40 60 80
Women
Age (years)
Prevalence of OA (%)
Age-Related Prevalence of OA:
Changes on X-Ray
DIP
Knee
Hip
DIP
Knee
Hip

Case 2: Distal and Proximal
Interphalangeal Joints

Radiograph shows
severe changes
Most common
location in hand
May cause significant
loss of function
Case 2: Carpometacarpal Joint

X-ray shows
osteophytes,
subchondral sclerosis,
and complete loss of
joint space
Patients often present
with deep groin pain
that radiates into the
medial thigh
Case 2: Hip Joint

What If Case 2 Had OA in the
“Wrong” Joint, eg, the Ankle?
•Then you must consider secondary causes of OA
•Ask about previous trauma and/or overuse
•Consider neuromuscular disease, especially
diabetic or other neuropathies
•Consider metabolic disorders, especially
CPPD (calcium pyrophosphate deposition
disease—aka pseudogout)

Secondary OA: Diabetic Neuropathy
MTPs 2 to 5 involved
in addition to the 1st
bilaterally
Destructive changes
on x-ray far in excess
of those seen in
primary OA
Midfoot involvement
also common

Underlying Disease Associations of
OA and CPPD Disease (pseudogout)
Hemochromatosis
Hyperparathyroidism
Hypothyroidism
Hypophosphatasia
Hypomagnesemia
Neuropathic joints
Trauma
Aging, hereditary

Management of OA
•Establish the diagnosis of OA on the basis of
history and physical and x-ray examinations
•Decrease pain to increase function
•Prescribe progressive exercise to
•Increase function
•Increase endurance and strength
•Reduce fall risk
•Patient education: Self-Help Course
•Weight loss
•Heat/cold modalities

Pharmacologic Management of OA
Nonopioid analgesics
Topical agents
Intra-articular agents
Opioid analgesics
NSAIDs
Unconventional therapies

Strengthening Exercise for OA
•Decreases pain and increases function
•Physical training rather than passive therapy
•General program for muscle strengthening
•Warm-up with ROM stretching
•Step 1:Lift the body part against gravity, begin
with 6 to 10 repetitions
•Step 2:Progressively increase resistance with
free weights or elastic bands
•Cool-down with ROM stretching
Rogind, et al. Arch Phys Med Rehabil. 1998;79:1421–1427.
Jette, et al. Am J Public Health.1999;89:66–72.

Reconditioning Exercise
Program for OA
•Low-impact, continuous movement exercise for
15 to 30 minutes 3 times per week
•Fitness walking: Increases endurance, gait
speed, balance, and safety
•Aquatics exercise programs—group support
•Exercycle with minimal or no tension
•Treadmill with minimal or no elevation

Nonopioid Analgesic Therapy
•First-line—Acetaminophen
•Pain relief comparable to NSAIDs, less toxicity
•Beware of toxicity from use of multiple
acetaminophen-containing products
•Maximum safe dose = 4 grams/day

Nonopioid Analgesic Therapy (cont’d)
•NSAIDs
•Use generic NSAIDs first
•If no response to one may respond to another
•Lower doses may be effective
•Do not retard disease progression
•Gastroprotection increases expense
•Side effects: GI, renal, worsening CHF, edema
•Antiplatelet effects may be hazardous

*P<.05
Bradley, et al. N Engl J Med.1991;325:87–91.
Ibuprofen vs Acetaminophen for
Knee OA—Equivalent Benefit0 0.2 0.4 0.6 0.8
HAQ Pain
Walking Pain
Rest Pain*
50 Ft Walk
HAQ Disability
Change in Score
2400 Ibuprofen
1200 Ibuprofen
Acetaminophen

Nonopioid Analgesics in OA
•Cyclooxygenase-2 (COX-2) inhibitors
•Pain relief equivalent to older NSAIDs
•Probably less GI toxicity
•No effect on platelet aggregation or bleeding
time
•Side effects: Renal, edema
•Older populations with multiple medical
problems not tested
•Cost similar to generic NSAIDs plus proton
pump inhibitor or misoprostol
Medical Letter.1999;41:11–12.

Medical Letter.1999;41:11–12.
Nonopioid Analgesics in OA (cont’d)
•Tramadol
•Affects opioid and serotonin pathways
•Nonulcerogenic
•May be added to NSAIDs, acetaminophen
•Side effects: Nausea, vomiting, lowered
seizure threshold, rash, constipation,
drowsiness, dizziness

Opioid Analgesics for OA
•Codeine, oxycodone
•Anticipate and prevent constipation
•Long-acting oxycodone may have fewer CNS
side effects
•Propoxyphene
•Morphine and fentanyl patches for severe pain
interfering with daily activity and sleep

Topical Agents for Analgesia in OA
•Local cold or heat: Hot packs, hydrotherapy
•Capsaicin-containing topicals
•Use well supported by evidence
•Use daily for up to 2 weeks before benefit
•Compliance poor without full instruction
•Avoid contact with eyes
•Liniments = methyl salicylates
•Temporary benefit

OA: Intra-articular Therapy
•Intra-articular steroids
•Good pain relief
•Most often used in
knees, up to q 3 mo
•With frequent
injections, risk
infection, worsening
diabetes, or CHF
•Joint lavage
•Significant
symptomatic benefit
demonstrated
•Hyaluronate injections*
•Symptomatic relief
•Improved function
•Expensive
•Require series of
injections
•No evidence of long-
term benefit
•Limited to knees
* Altman, et al. J Rheumatol.1998;25:2203.

OA: Unconventional Therapies
•Polysulfated glycosaminoglycans—nutriceuticals
•Glucosamine +/-chondroitin sulfate:
Symptomatic benefit, no known side effects,
long-term controlled trials pending
•Tetracyclines as protease/cytokine inhibitors
•Under study
•Have disease-modifying potential

OA: Unconventional Therapies (cont’d)
•Keep in touch with current information. The
unconventional may become conventional
•www.quackwatch.com
•ACR Website
(http://www.rheumatology.org)
•Arthritis Foundation Website
(www.arthritis.org)

Surgical Therapy for OA
•Arthroscopy
•May reveal unsuspected focal abnormalities
•Results in tidal lavage
•Expensive, complications possible
•Osteotomy: May delay need for TKR for
2 to 3 years
•Total joint replacement: When pain severe and
function significantly limited

OA: Management Summary
•First: Be sure the pain is joint related (not a
tendonitis or bursitis adjacent to joint)
•Initial treatment
•Muscle strengthening exercises and
reconditioning walking program
•Weight loss
•Acetaminophen first
•Local heat/cold and topical agents

OA: Management Summary (cont’d)
•Second-line approach
•NSAIDs if acetaminophen fails
•Intra-articular agents or lavage
•Opioids
•Third-line
•Arthroscopy
•Osteotomy
•Total joint replacement
Tags